Perspective Therapeutics, Inc.
CATX
$1.94
$0.094.87%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.45M | 1.56M | 1.46M | 1.53M | 1.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.45M | 1.56M | 1.46M | 1.53M | 1.43M |
| Cost of Revenue | 39.43M | 20.34M | 20.34M | 20.34M | 20.34M |
| Gross Profit | -37.74M | -18.79M | -18.88M | -18.82M | -18.91M |
| SG&A Expenses | 26.61M | 23.31M | 20.81M | 20.28M | 21.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 15.00K | 15.00K | 0.00 | 0.00 |
| Total Operating Expenses | 68.25M | 59.16M | 50.18M | 45.73M | 42.38M |
| Operating Income | -66.80M | -57.60M | -48.72M | -44.21M | -40.94M |
| Income Before Tax | -80.43M | -49.86M | -44.31M | -42.52M | -40.11M |
| Income Tax Expenses | -2.10M | 7.85M | 7.85M | 7.85M | -2.65M |
| Earnings from Continuing Operations | -78.33 | -57.71 | -52.16 | -50.37 | -37.46 |
| Earnings from Discontinued Operations | -949.00K | -6.07M | -6.86M | -8.05M | -9.05M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.28M | -63.79M | -59.02M | -58.42M | -46.51M |
| EBIT | -66.80M | -57.60M | -48.72M | -44.21M | -40.94M |
| EBITDA | -84.68M | -55.76M | -47.27M | -43.07M | -39.96M |
| EPS Basic | -1.21 | -1.52 | -1.67 | -1.89 | -1.66 |
| Normalized Basic EPS | -0.55 | -0.65 | -0.73 | -0.83 | -0.94 |
| EPS Diluted | -1.78 | -1.52 | -1.67 | -1.89 | -1.66 |
| Normalized Diluted EPS | -0.55 | -0.65 | -0.73 | -0.83 | -0.94 |
| Average Basic Shares Outstanding | 257.61M | 214.87M | 172.30M | 133.65M | 107.00M |
| Average Diluted Shares Outstanding | 257.61M | 214.87M | 172.30M | 133.65M | 107.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |